Additionally, a clinical phase I/II with an IDO inhibitor (BMS-986205) in combination with nivolumab showed promising results, with response rates of 46% in bladder cancer and 25% in cervical cancer (Blocking IDO1 Helps Shrink Bladder, Cervical Tumors, 2018). This evidence concerns the gene IDO1 and urinary bladder carcinoma.